Navigation Links
Queensland Facility for Advanced Bioinformatics (QFAB) Becomes a GeneGo Center of Excellence for the Asia Pacific Region
Date:2/2/2009

ST. JOSEPH, Mich., Feb. 2 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that QFAB has licensed MetaCore and entered a co marketing agreement with GeneGo for the Asia Pacific region. QFAB will have GeneGo certified experts on staff to run training classes in the region and support the local research community. QFAB will make MetaCore pathway tools, software and manually curated databases accessible to Australian and New Zealand academics as part of its delivery of tailored bioinformatics solutions to life science researchers in the region.

Jeremy Barker, QFAB's Chief Executive Officer said, "We are currently using MetaCore for an in-house project and have seen the power that it provides in a systems biology framework. In partnering with GeneGo we aim to help researchers in our part of the world realize the benefits that can come from using this software."

"We are very excited about this relationship as we will work together to open up and support Australia, New Zealand and beyond," said Julie Bryant, GeneGo's VP of Business development. "We will be jointly supporting a lot of marketing and research activities in the region as there is a lot of exciting and novel research we would like to be involved in."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Open Biosystems Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
2. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
3. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
4. Hovione Buys Pfizers Loughbeg API Facility
5. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
6. Vicenza Hospital Becomes First European Facility to Purchase Its Second CyberKnife System
7. Nikon Instruments Provides Donation to Help Clemson University Start New Core Microscopy Facility
8. BioLife Solutions Credit Facility Increased to $9 Million
9. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
10. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
11. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
Breaking Biology News(10 mins):